Tumor regression by means of magnetic drug targeting.
The expression 'magnetic drug targeting' is understood as meaning the targeted administration of a drug, for example, a cytostatic, with the intention of optimizing the local therapeutic effect. A magnetic field strength of 0.6 T is applied externally to the body. Iron oxides are administered intravasally into a vein. Cytostatics are bonded to the iron oxides. This form of administration, also known as sluicing, is particularly suitable for cytostatics, since the intention is to achieve a high concentration of the cytostatic at the target site (site of the tumor), but to minimize the harmful effect in the rest of the tissue. A reduction in tumor volume under the magnetic field and in the liver of 45-90% has been detected by MRI.